A. Mardinoglu*, J. Borén, U. Smith, M. Uhlén and J. Nielsen, Systems biology in hepatology: approaches and applications, Nature Reviews Gastroenterology & Hepatology, 15, 365–377, 2018.
A. Mardinoglu and J. Nielsen, Systems medicine and metabolic modelling, Journal of Internal Medicine, 271, 142–154, 2012.
A. Mardinoglu, R. Agren, C. Kampf, A. Asplund, M. Uhlen and J. Nielsen, Genome-scale metabolic modeling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease, Nature Communications, 5:3083, 2014.
C. Kampf#, A. Mardinoglu#, L. Fagerberg, B. Hallström, K. Edlund, F. Pontén, J. Nielsen, M. Uhlen, The human liver-specific proteome defined by transcriptomics and antibody-based profiling, Faseb Journal, 28, 2901-2914, 2014.
A. Mardinoglu*, E. Bjornson, C. Zhang, M. Adiels, N. Lundblom, A. Hakkarainen, J. Lundbom, P H R Barrett, G. F Watts, U. Smith, H. Marschall, J. Nielsen, M. Taskinen and J. Boren, Personalized genome-scale modeling identifies NAD+ and glutathione metabolism as a target for treatment of NAFLD, Molecular Systems Biology, 13:916, 2017.
J. Bosley, C. Boren, S. Lee, M. Grøtli, J. Nielsen, J. Boren, M. Uhlen, A. Mardinoglu*, Improving economics of NASH/NAFLD treatment through the use of systems biology, Drug Discovery Today, 2017.
A. Mardinoglu, D. Ural, M. Zeybel, M. Uhlén, J. Borén, The potential use of metabolic cofactors in treatment of NAFLD, Nutrients, 2019.
O. Altay, J. Nielsen, M. Uhlen, J. Boren, A. Mardinoglu, A systems biology perspective for studying the human liver-gut microbiome axis, EbioMedicine, 2019.
S. Lam, S. Doran, H. H. Yuksel, O. Altay, H. Turkez, J. Nielsen, J. Boren, M. Uhlen, A. Mardinoglu, Addressing the heterogeneity in liver diseases using biological networks, Briefing in Bioinformatics, 2020.
C. Zhang, E. Bjornson, J. Bosley, M. Arif, A. Lovric, S. Lee, G. Bidkhori, R. Benfeitas, M. Ståhlman, PO Bergh, M. Adiels, J. Nielsen, M. Uhlén, HU Marschall, J. Borén, A. Mardinoglu*, The acute effect of metabolic cofactor supplementation: a potential therapeutic strategy against non‐alcoholic fatty liver disease, MSB, 2020.
